A phase 2 open-label study published in the American Cancer Society’s journal CANCER demonstrates that a single 25 mg dose of psilocybin, combined with psychological support, produces sustained improvements in depression and anxiety among cancer patients with major depressive disorder. Over half of participants experienced significant symptom reduction two years post-treatment. This research highlights psilocybin’s potential as a novel psychiatric intervention for psychological distress in oncology settings.